drugset
drugset / Trial / NCT05306366

A Brain Imaging PET Study of [11C]-Lu AF90103 in Healthy Adult Male Participants

NCT05306366 ↗

Phase 1 Completed 8 enrolled H. Lundbeck A/S
NaSingle-groupOpen-labelTreatment

Summary

The main goals of the study are to assess uptake and distribution of Lu AF90103 in the brain when given at tracer levels (microdose) in healthy young men.

Timeline

Start
2022-03-23
Primary completion
2022-06-07
Completion
2022-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AF90103 Unknown — Intravenous

Indications

No indication recorded.